Acarix partners with Strategic Health AK to roll-out CADScor®System across the state of Alaska


Acarix continues its US expansion by partnering with Strategic Health AK, a healthcare provider covering tribal and rural areas of Alaska. Acarix has received initial orders of CADScor®Systems to be used across health regions in Alaska.

Read the English release here

Read the Swedish release here




About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, is Certified Advisor of Acarix.

For more information, please visit